Clover Health has spent the past month forcing short sellers to reconsider, with a 37.5% price gain since early May now coinciding with a dramatic unwind of bearish positions — the story this week is whether the covering continues or the rally runs out of room.
The short interest decline has been the defining move of recent weeks. Shorts have cut their exposure by nearly 30% over the past month, with the sharpest drop arriving this week: estimated short interest fell 16% over five sessions to 6.3% of free float, with another 12% shed on Tuesday alone. At roughly 26.6 million shares short, the position is at its smallest in the 30-day window. The borrow market tells a complementary story — availability has loosened significantly, now running at 287%, well up from readings closer to 130% in late April. Borrowing costs have drifted lower too, to around 0.4%. None of that signals squeeze pressure. The covering looks orderly: shorts are exiting into price strength, not being forced out by a tightening lending market. Options traders reinforce the bullish lean, with the put/call ratio at 0.24 — well below its 20-day average of 0.29 and near the lower end of its year-long range — suggesting call demand is driving the options market rather than hedging.
The Street has only partially kept pace with the move. Canaccord Genuity lifted its target to $4.20 from $3.20 on June 4, keeping its Buy rating, and that revision now sits almost exactly at the current price of $4.29. The consensus mean target of $3.48 is already below where the stock trades, making the Street structurally underweight on price expectations relative to the tape. The bull case centres on Clover's upgrade to a CMS 4-star plan for 2026, which unlocks better reimbursement rates and a stronger recruiting pitch for new Medicare Advantage members. Bears counter that the track record on sustained profitability is thin and that competitive pressures in managed care remain intense. Valuation has re-rated sharply alongside the price: the P/E has expanded roughly 19% over the past month to around 45x, and price-to-book is up a similar magnitude to 5.7x. EPS momentum factor scores remain strong — ranking in the 94th percentile on 30-day momentum — but the short score has been falling steadily, dropping from 59 a week ago to 53 now, reflecting the easing short-side pressure.
One note on insider activity cuts against the bullish positioning. Every transaction in the insider table over the past 90 days has been a sale. The CEO of a subsidiary, a division CEO, the acting CFO, an independent director, and a regional president have all sold shares since mid-April, collectively generating a net sale of just over $3.3 million across the 90-day window. Most are modest in size and some look like routine plan-driven sales, but the direction is uniform — no insider has been a buyer into this rally.
On the peer front, the sector backdrop has turned more helpful. HUM gained 13% on the week and AGL rose nearly 18%, suggesting a broader re-rating across managed care names rather than a CLOV-specific story. That context matters for gauging how sticky the move is: if the sector tailwind fades, CLOV loses one of its current supporting pillars.
The next scheduled earnings event is August 5, leaving roughly eight weeks for positioning to consolidate — the more immediate question is whether short sellers continue covering at this pace or whether, with borrow loose and the stock already up 37% in a month, the remaining bears decide the thesis still has merit above $4.
See the live data behind this article on ORTEX.
Open CLOV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
